沐舒坦品牌怎么样 申请店铺

外推网助力沐舒坦品牌出海！将品牌入驻外推网，定制沐舒坦品牌推广信息，可以显著提高沐舒坦产品曝光，简直是跨境电商爆单神器！目前仅需1000元/年哦~

勃林格殷格翰是目前世界上最大、最成功的私人拥有的制药集团。自1885年成立至今，家族拥有的勃林格殷格翰一直致力于研发、生产和营销创新的药品。我们的主要业务包括处方药，消费自主保健药品，生物制药及动物保健。经过百年的发展，勃林格殷格翰的足迹从德国莱茵河畔延伸向全球40多个国家和地区，并成功跻身全球前二十位制药企业之列。
在全球

1885年，阿尔伯特.勃林格先生在德国法兰克福附近的殷格翰城创立了勃林格殷格翰公司。

一百多年来，研究与开发驱动着公司的发展。从最初生产酒石酸，乳酸等化工产品开始，到今天许多广为人知药品的推出，勃林格殷格翰公司在研发上的巨额投入使其在呼吸、、心血管、中枢神经、肠胃道等领域拥有优秀的产品，从而赢得有利的市场地位；同时勃林格殷格翰的科学家也数次获得包括诺贝尔奖在内的学术界殊荣。至今公司已在德国、意大利、奥地利、美国、加拿大、阿根廷和日本设立7大研发中心并投入巨资用于新产品的研究与开发。
在中国

1994年3月勃林格殷格翰以办事处的形式进入中国，揭开了在中国的发展篇章。1995年5月，勃林格殷格翰国际贸易（上海）有限公司注册成立。1998年初进驻上海张江“药谷”成立上海勃林格殷格翰药业有限公司，投资额达2900万美元，标志着勃林格扎根中国的决心。位于张江的现代化工厂，引进了世界先进的制药设备，设计和管理标准可以和任何其它国家的勃林格殷格翰工厂媲美。工厂严格按照国际GMP标准生产。

勃林格殷格翰在中国的主要业务包括处方药，消费者自主保健药品及动物保健。业务范围遍及全国各主要省市和地区。公司不断把其优秀的产品带来中国市场，上市的产品覆盖呼吸、心血管、中枢神经、抗爱滋病等重要领域，并在业界和市场获得了广泛的美誉和认可。
保健业务

随着人们自我保健意识的提高,用于维持和改善健康、预防疾病,及治疗一些轻微疾病如感冒咳嗽等的消费者自主保健药品正越来越显示其重要性。勃林格殷格翰自主保健药品部致力于非处方药和保健食品的研制生产和销售。2005年销售额名列全球非处方药生产企业第8位，旗下产品线主要涵盖身心健康，感冒咳嗽，解热镇痛及血管保健等四大品类，并有众多品牌在各自领域在全球销售名列前茅。如沐舒坦和必嗽平分别占据祛痰药市场的第一和第二位置；富马(Pharmaton)系列产品名列维生素和矿物质补充剂产品第二位；乐可舒(Dulcolax)在缓泄剂市场排名第一。

作为勃林格殷格翰公司的核心业务之一，我们致力于为中国的消费者提供最高品质的自主保健药品。沐舒坦®片剂和口服溶液均已进入非处方药目录，是中国祛痰止咳市场的第一品牌。它能有效调节气道的浆液和粘液分泌，活化纤毛粘液运输系统，能发挥表面活性物质的正常保护功能，因而廓清效果深入肺泡，被称为“全肺动力型排痰剂”，更有“呼吸道清道夫”的美称。沐舒坦疗效显著，深受广大患者欢迎，而口服溶液更因可口的水果口味得到儿童和家长的喜欢。
公益事业

造福社会回馈社会，是勃林格的一贯作风，公司从进入中国市场后就积极投身于中国的公益事业。公司向中国卫生部捐赠抗病毒药品维乐命用于阻断艾滋病母婴传播项目。SARS期间，向北京和上海的有关部门捐赠药品和医疗仪器用于支持抗非斗争。以及赞助国家劳动社会保障部关于社区卫生服务与医疗保险作用研究等。
共同愿景

“创新展新价值”是勃林格殷格翰公司的远景。作为一个有着百年历史却始终充满活力的企业,勃林格殷格翰以服务人类健康为使命，致力于关键领域疾病研究和新药及新的治疗方法开发,视客户需求为最大关注。我们深信，本着不断创新的开拓精神，公司将进一步保持发展，展现令人期待的繁荣前景。

Bringer ingelham is the largest and most successful privately owned pharmaceutical group in the world. Since its establishment in 1885, the family owned Boehringer Ingelheim has been committed to the research, development, production and marketing of innovative drugs. Our main businesses include prescription drugs, consumer self-care drugs, biopharmaceuticals and animal health care. After a hundred years of development, Boehringer Ingelheim's footprint has extended from the Rhine River in Germany to more than 40 countries and regions around the world, and has successfully become one of the top 20 pharmaceutical enterprises in the world. In 1885, Albert bringer founded the company in the city of Ingelheim near Frankfurt, Germany. For more than 100 years, research and development has driven the development of the company. From the initial production of tartaric acid, lactic acid and other chemical products to the launch of many well-known drugs today, the company's huge investment in research and development has made it have excellent products in the fields of respiration, cardiovascular, central nervous system, gastrointestinal tract and other fields, thus winning a favorable market position; at the same time, the scientists of the company have won several times, including the Nobel Prize It's a great honor in the academic circle. So far, the company has set up 7 R & D centers in Germany, Italy, Austria, the United States, Canada, Argentina and Japan, and invested heavily in the research and development of new products. In March 1994, Brigitte Ingelheim entered China in the form of an office, opening a chapter of development in China. In May 1995, bringer Ingelheim international trade (Shanghai) Co., Ltd. was registered and established. At the beginning of 1998, Shanghai bolingeringelheim Pharmaceutical Co., Ltd. was established in Zhangjiang "pharmaceutical Valley" in Shanghai, with an investment of 29 million US dollars, marking Bolinger's determination to take root in China. The modern chemical plant in Zhangjiang has introduced the world's advanced pharmaceutical equipment, and its design and management standards can be comparable to those of any other country's bringer Ingelheim plant. The factory strictly follows the international GMP standard production. The main business of Boehringer Ingelheim in China includes prescription drugs, consumer independent health care drugs and animal health care. The business scope covers all major provinces, cities and regions of the country. The company continues to bring its excellent products to the Chinese market. The products on the market cover breathing, cardiovascular, central nervous system, anti AIDS and other important fields, and have gained a wide reputation and recognition in the industry and market. With the improvement of people's awareness of self-care, the importance of consumer self-care drugs used to maintain and improve health, prevent diseases, and treat some minor diseases such as cold and cough is becoming more and more obvious. Boehringer Ingelheim independent health medicine department is committed to the development, production and sales of over-the-counter drugs and health food. In 2005, its sales volume ranked the 8th in the world's over-the-counter drug manufacturers. Its product line mainly covers four categories, including physical and mental health, cold and cough, antipyretic and analgesic, and vascular health care. Many brands rank first in the global sales in their respective fields. For example, Mucosolvan and bissouping occupy the first and second positions in the expectorant market respectively; pharmaton series products rank second in vitamin and mineral supplement products; Dulcolax ranks first in the relief market. As one of the core businesses of Boehringer Ingelheim, we are committed to providing Chinese consumers with the highest quality independent health care drugs. Both ambroxol & reg; tablets and oral solutions have entered the over-the-counter drug list and are the first brand in the expectorant and cough relieving market in China. It can effectively regulate the secretion of the airway slurry and mucus, activate the ciliated mucus transport system, and play the normal protective function of surfactant. Therefore, the clearance effect goes deep into the alveoli, which is called "all lung dynamic expectorant" and "respiratory scavenger". Ambroxol is very effective and popular among patients, while oral solution is popular among children and parents for its delicious fruit taste. It is a consistent style of Bolinger that public welfare undertakings benefit the society and give back to the society. Since entering the Chinese market, the company has been actively engaged in public welfare undertakings in China. The company donated antiviral drug velocin to the Ministry of health of China to block mother to child transmission of AIDS. During the period of SARS, drugs and medical instruments were donated to relevant departments in Beijing and Shanghai to support the fight against Africa. As well as sponsoring the research of the Ministry of labor and social security on the role of community health services and medical insurance. The shared vision of "innovation and new value" is the vision of bringer Ingelheim. As an enterprise with a history of one hundred years but full of vitality all the time, Boehringer Ingelheim takes serving human health as its mission, devotes itself to disease research and development of new drugs and new treatment methods in key fields, and takes the needs of customers as the greatest concern. We firmly believe that in the spirit of continuous innovation and pioneering spirit, the company will further maintain development and show a promising prospect of prosperity.

本文链接： https://brand.waitui.com/b627c0452.html 联系电话：请联系客服添加 联系邮箱：请联系客服添加